Detailed Study Description

Patients will be randomized in a 1:1 to receive treatment with durvalumab + tremelimumab
combination therapy or SoC therapy. The primary objective of this study is to assess the
efficacy of combination treatment compared with SoC in terms of Overall Survival (OS) in
patients.